A Study Evaluating the Safety, Activity, and Pharmacokinetics of Divarasib as a Single Agent or in Combination With Other Anti-Cancer Therapies in Participants With Previously Untreated Advanced or Metastatic Non-Small Cell Lung Cancer With a KRAS G12C Mutation

Percentage of Participants with Adverse Events (AEs)

Timeframe: Baseline until 60 days after the final dose of study treatment or until initiation of another anti-cancer therapy, whichever occurs first (up to approximately 5 years)

Objective Response Rate (ORR)

Timeframe: Approximately 5 years

The percentage of participants who experience a complete response or partial response, as determined by the investigator, according to Response Evaluation Criteria in Solid Tumors (RECIST) v1.1

Duration of Response (DOR)

Timeframe: Approximately 5 years

The time from the first occurrence of a documented objective response to disease progression or death from any cause (whichever occurs first), as determined by the investigator according to RECIST v1.1

Progression Free Survival (PFS)

Timeframe: Approximately 5 years

The time from randomization, or date of first treatment for participants enrolled prior to the expansion stage, to the first occurrence of disease progression or death from any cause during the study (whichever occurs first), as determined by the investigator according to RECIST v1.1

Number of Participants Reporting Presence, Frequency, Severity, and/or Degree of Interference with Daily Function of Symptomatic Side Effects as Assessed Through the Patient-Reported Outcomes Common Terminology Criteria for Adverse Events (PRO-CTCAE)

Timeframe: Approximately 5 years

Change from Baseline in Symptomatic Side Effects, as Assessed Through use of the PRO-CTCAE

Timeframe: Baseline up to approximately 5 years

Percentage of Participants Reporting "Frequent" or "Almost Constant" Diarrhea During the First Three Cycles of Treatment According to the PRO-CTCAE Criteria

Timeframe: Approximately 5 years

Percentage of Participants Reporting "Severe" or "Very Severe" Nausea or Vomiting During the First Three Cycles of Treatment According to the PRO-CTCAE

Timeframe: Approximately 5 years

Frequency of Participant's Response of the Degree they are Troubled with Treatment Symptoms, as Assessed Through use of the Single-item European Organisation for Research and Treatment of Cancer (EORTC) Item List 46 (IL46)

Timeframe: Approximately 5 years

Plasma or CSF Concentration of Divarasib at Specified Timepoints

Timeframe: Approximately 5 years

Optional CSF samples may be collected at the time of disease progression or at any time during the study for participants who have provided written consent and if collection of CSF sample is deemed clinically feasible. Matched optional plasma samples may be drawn at the same time.

Identification of Divarasib Recommended Dose

Timeframe: Approximately 5 years

The recommended dose will be based upon the totality of safety, activity, and PK data.

Central Nervous System (CNS) Response

Timeframe: Approximately 5 years

Defined as the percentage of participants who experience a complete response or partial response in the brain, as determined by the investigator according to modified RECIST